Neal Walker Aclaris Therapeutics, Inc. (ACRS) insider trading activity

Neal Walker is INTERIM CEO of Aclaris Therapeutics, Inc.. Currently has a direct ownership of 1.43 Million shares of ACRS, which is worth approximately $4.19 Million. The most recent transaction as insider was on Mar 02, 2023, when has been sold 18,254 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.43M

5.19% 3M change

12.6% 12M change

Total Value Held $4.19 Million

Neal Walker Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 02 2023	BUY Exercise of conversion of derivative security	-	18,254 Added 1.38%	1,303,442 Common Stock
Mar 01 2023	BUY Exercise of conversion of derivative security	-	138,425 Added 9.53%	1,314,188 Common Stock
Feb 02 2023	SELL Open market or private sale	$80,700 $16.14 p/Share	5,000 Reduced 0.42%	1,175,763 Common Stock
Feb 01 2023	SELL Open market or private sale	$418,750 $16.75 p/Share	25,000 Reduced 2.07%	1,180,763 Common Stock
Jan 04 2023	SELL Open market or private sale	$223,350 $14.89 p/Share	15,000 Reduced 1.23%	1,205,763 Common Stock
Jan 03 2023	SELL Open market or private sale	$392,000 $15.68 p/Share	25,000 Reduced 2.01%	1,220,763 Common Stock
Apr 25 2022	SELL Open market or private sale	$303,600 $15.18 p/Share	20,000 Reduced 1.58%	1,245,763 Common Stock
Apr 22 2022	SELL Open market or private sale	$376,000 $15.04 p/Share	25,000 Reduced 1.94%	1,265,763 Common Stock
Apr 21 2022	SELL Open market or private sale	$381,000 $15.24 p/Share	25,000 Reduced 1.9%	1,290,763 Common Stock
Mar 11 2022	SELL Open market or private sale	$895,781 $15.91 p/Share	56,303 Reduced 4.1%	1,315,763 Common Stock
Mar 02 2022	BUY Exercise of conversion of derivative security	-	18,254 Added 1.31%	1,372,066 Common Stock
Mar 01 2022	BUY Exercise of conversion of derivative security	-	114,425 Added 7.79%	1,353,812 Common Stock
Feb 09 2022	SELL Open market or private sale	$45,513 $12.66 p/Share	3,595 Reduced 0.29%	1,239,387 Common Stock
Feb 01 2022	BUY Exercise of conversion of derivative security	-	10,800 Added 0.86%	1,242,982 Common Stock
Jun 02 2021	SELL Open market or private sale	$728,727 $21.91 p/Share	33,260 Reduced 2.63%	1,232,182 Common Stock
Jun 01 2021	BUY Exercise of conversion of derivative security	-	73,015 Added 5.46%	1,265,442 Common Stock
Apr 22 2021	SELL Open market or private sale	$805,200 $26.84 p/Share	30,000 Reduced 2.45%	1,192,427 Common Stock
Mar 02 2021	SELL Payment of exercise price or tax liability	$185,582 $23.25 p/Share	7,982 Reduced 0.65%	1,222,427 Common Stock
Mar 02 2021	BUY Exercise of conversion of derivative security	-	18,253 Added 1.46%	1,230,409 Common Stock
Mar 01 2021	SELL Payment of exercise price or tax liability	$957,395 $24.06 p/Share	39,792 Reduced 3.18%	1,212,156 Common Stock
Mar 01 2021	BUY Exercise of conversion of derivative security	-	96,150 Added 7.13%	1,251,948 Common Stock
Feb 01 2021	SELL Payment of exercise price or tax liability	$70,797 $21.35 p/Share	3,316 Reduced 0.29%	1,155,798 Common Stock
Feb 01 2021	BUY Exercise of conversion of derivative security	-	10,800 Added 0.92%	1,159,114 Common Stock
Dec 15 2020	SELL Payment of exercise price or tax liability	$3,998 $4.59 p/Share	871 Reduced 0.08%	1,148,314 Common Stock
Dec 15 2020	BUY Exercise of conversion of derivative security	-	3,034 Added 0.26%	1,149,185 Common Stock

Also insider at

ALDX

Aldeyra Therapeutics, Inc. Healthcare

Neal Walker

INTERIM CEO

Wayne, PA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ACRS shares.

Notify only if

Value

Insider Trading

Get notified when an Aclaris Therapeutics, Inc. insider buys or sells ACRS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Aclaris Therapeutics, Inc.

Track Activities on ACRS

Account